The relevant role of the block of cell differentiation in the oncogenic effects of FLT3-ITD is directly supported by a recent clinical observation made in a group of AML patients with FLT3-ITD+ AML and with normal karyotype treated with quizartinib (also known as AC220) [71]. The gene discussed is FLT3; the disease is acute myeloid leukemia.